FSI “SID & GP” AND SAUDI ARABIA’S SFDA SIGN MEMORANDUM AT SPIEF-2026

On June 4, 2026, the FSI “State Institute of Drugs and Good Practices” (FSI “SID & GP”) of the Russian Ministry of Industry and Trade and the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia entered into a Memorandum of Understanding. The document, aimed at advancing cooperation on GMP inspections between the two countries, was inked on the sidelines of the 29^th St Petersburg International Economic Forum (SPIEF).

The Memorandum envisages the establishment of a bilateral exchange of information and best practices in the regulation and monitoring of various types of medicinal products, including innovative drugs manufactured using biotechnology and artificial intelligence. Furthermore, the parties intend to focus on building the competencies for their respective GMP inspectorates.

The document was signed by Vladislav Shestakov, Director of FSI “SID & GP,” and Sami AlSager, Executive Vice President for the Operations Sector at the SFDA of the Kingdom of Saudi Arabia.

“The MoU marks a new chapter in Russia-Saudi cooperation on GMP inspections. Recognizing the importance of interaction and trust-building between the regulatory systems of the two countries, we are joining forces to ensure people have access to effective, safe, and high-quality medicinal products. Through joint development of regulatory systems and good manufacturing practice, we will be able to put in place a transparent framework for pharmaceutical regulation,” noted Vladislav Shestakov, Director of FSI “SID & GP.”